Life sciences and medical diagnostics company Danaher (DHR) reported better-than-expected earnings and revenue for the fourth quarter. We view the dip in the stock as unjustified and an opportunity. Revenue increased nearly 10% on a core basis to $8.37 billion, well above estimates of $7.9 billion, according to Refinitiv. Adjusted profit increased 6.7% to $2.87 per share, exceeding the consensus estimate of $2.54 per share. When excluding the impact of declining Covid testing sales — but keeping in revenue from products that support vaccines and therapeutics — Danaher’s base business saw core growth of 7.5%. That shows the company isn’t overly reliant on the bump in pandemic sales. Bottom line This was a solid quarter from one of the best-run companies in the world. With very little to nitpick, we attribute Tuesday’s 3% stock decline to a combination of management already preannouncing the results and shares making a large move into the print. Also to blame: first-quarter guidance may be a tad light versus expectations. Given in-line to better-than-expected quarterly results pretty much across the board along with operating margin expansion and strong cash flow generation, we’re inclined to view Tuesday’s selloff as a buying opportunity as noted by […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
